Peak Hours News – Investing tips, Stock, Economy News
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Stock

Will BioNtech sustain the $140 support level?

by May 13, 2022
written by May 13, 2022

BioNtech SE (NASDAQ: BNTX) is bullish this week, having gained 16.03% to trade at $158. The gains come after the company reported growth in vaccine sales. The company still expects vaccine sales to decline. This week’s rally comes after the company announced the completion of Phase II coronavirus vaccine trials in China.

BioNtech is a fundamentally strong stock. The company has more than $10 billion in cash, based on the Q1 report. BioNtech has been among the fast-growing stocks. The company is A-rated on value and growth. The F-rating on momentum means the stock is unlikely to maintain the current price trend.

A recent partnership in China where new coronavirus outbreaks are being recorded creates unique opportunities for BioNtech. Though vaccine sales to the rest of the world may decline, BioNtech will be supported by the Chinese partnership. The company remains fundamentally strong, and the strength will continue supporting the stock.

BioNtech consolidates between $140 and $180

Source – TradingView

Technical analysis shows that BioNtech continues to consolidate prices between $140 support and $180 resistance. The prices are projected to remain within this range for the better part of this year. The RSI has pointed to a potential upward trend. Nonetheless, this analysis considers that the RSI will remain between 40 and 50 for the foreseeable future.

Summary

BioNtech remains fundamentally strong on value and growth investing styles. Recent success in coronavirus vaccine Phase II trials in China will prop the decline in sales to other markets. The stock will remain between $130 and $180 as the recession bites.

The post Will BioNtech sustain the $140 support level? appeared first on Invezz.

0 comment
0
FacebookTwitterPinterestEmail

previous post
Duke Realty increases by 10% after proposed acquisition announcement
next post
What next as Moderna finds support at $130?

You may also like

SDY stock: Is this dividend aristocrat ETF a...

May 30, 2023

ZIM Integrated Shipping stock price: the plot thickens

May 30, 2023

3 overbought US sectors to watch in the...

May 30, 2023

IDS share price: Here’s why I’d never buy...

May 30, 2023

Rolls-Royce share price outlook as volatility, volume slips

May 30, 2023

Rivian stock price forecast: Here’s why I’m buying...

May 30, 2023

Samsung vs TSMC stock: Susquehanna analyst picks a...

May 29, 2023

Nasdaq statistics in 2023

May 29, 2023

Professor Jeremy Siegel on AI stocks: ‘it’s not...

May 29, 2023

Debt ceiling deal: will the U.S. stocks rally...

May 29, 2023
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Recent Posts

  • My £200 weekly passive income plan

    June 10, 2023
  • 5 simple Warren Buffett moves for small investors

    June 10, 2023
  • I’m taking this once-in-a-lifetime opportunity to buy dirt cheap UK dividend shares

    June 10, 2023
  • Here’s why Scottish Mortgage shares jumped 11% in May

    June 10, 2023
  • Binance to Remove 102 Spot Trading Pairs and Halt OTC Services

    June 10, 2023

Categories

  • Economy (14,251)
  • Editor's Pick (1,005)
  • Investing (371)
  • Stock (3,858)
About Us Terms & Conditions Privacy Policy Email WhiteListing Contact Us

Disclaimer: Peakhoursnews.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2023 PeakHoursNews.com. All Rights Reserved.


Back To Top
Peak Hours News – Investing tips, Stock, Economy News
  • Investing
  • Stock
  • Economy
  • Editor’s Pick